Chronic kidney disease (CKD) affects nearly 15% of US adults and is associated with diminished quality of life and reduced life expectancy. June’s Journal Club examines new, favorable clinical trial data on dapagliflozin use in patients with CKD to improve renal outcomes and provide glycemic control.  

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the mechanism of action and clinical pearls of dapagliflozin
2. Compare and contrast dapagliflozin with other available sodium-glucose co-transporter 2 (SGLT2) inhibitors
3. Discuss clinical trial data on dapagliflozin’s effect on renal outcomes
4. Identify patients who are candidates to receive dapagliflozin
5. Develop a conclusion for the clinical appropriateness of care based on a clinical trial

Kimmy Nguyen, PharmD, BCACP, BC-ADM
Assistant Professor
Wilkes University
Nesbit School of Pharmacy

Kimmy Nguyen does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Heerspink H, Stefánsson B, Correa-Rotter, R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:1436-1446. DOI: 10.1056/NEJMoa2024816. https://www.nejm.org/doi/full/10.1056/NEJMoa2024816 

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Subscription Service. To get more courses like this sent to you every month, sign-up for a CE Subscription Service!

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: June 9, 2021
Planned Expiration Date: June 9, 2024

RV3-3.24/EXP